
Articles
-
1 week ago |
healio.com | Regina Schaffer
Key takeaways: Systemic control of inflammation with upadacitinib may reduce cardiovascular event risk in adults with atopic dermatitis. Treated adults with AD had fewer heart events compared with real-world populations. Adults with atopic dermatitis treated with upadacitinib had fewer major adverse cardiovascular events compared with background rates in real-world populations, adding to research supporting the drug’s potential cardioprotective benefits.
-
2 weeks ago |
healio.com | Regina Schaffer
Key takeaways:Research suggests the impact of pregnancy on melanoma risk remains unclear. Any observed changes in melanocytic nevi during pregnancy should be considered suspicious unless proven otherwise. Alterations in the size and number of moles are commonly reported among the many changes taking place during pregnancy; however, what such changes might mean when it comes to melanoma risk remains an open question.
-
2 weeks ago |
healio.com | Regina Schaffer
Key takeaways:A wearable electrical stimulation device improved hair density and thickness for men with androgenic alopecia. The device was safe and well tolerated. In a small pilot study, men with androgenic alopecia saw improvements in hair density and thickness after 6 months of daily, 30-minute treatments with a wearable, low-level electrical stimulation device, researchers reported.
-
3 weeks ago |
healio.com | Regina Schaffer
Key takeaways: Adults living in low-resource neighborhoods were more likely to be diagnosed with hidradenitis suppurativa. More research is needed on social factors where people live and work. Dermatology patients living in the most disadvantaged neighborhoods were three times more likely to receive a diagnosis of hidradenitis suppurativa, suggesting social and environmental factors may play a role in disease development.
-
3 weeks ago |
healio.com | Regina Schaffer
Key takeaways: Oral semaglutide reduced risk for cardiovascular events in people with type 2 diabetes, atherosclerotic CVD and kidney disease. It is now the first and only oral GLP-1 receptor agonist with proven CV benefit. CHICAGO — Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 inhibitor use, according to data presented at the American College of Cardiology Scientific Session.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →